APASL 2015 ABSTRACT AWARDS ORAL PRESENTATIONS POSTER PRESENTATIONS 1416 Aichao Shi 1312 Qing Xie 1383 Andrew Muir 1204 Frederick Poordad 1506 Masao Omata 1456 Wenwen Li 1362 Yoshiyuki Wada 1303 Graham Foster 1287 Kazuya Okushin 1161 Ramazan Idilman KCTD9 CONTRIBUTES TO NK CELL ACTIVATION MAY THROUGH KCTD9 - SHB PATHWAY ADDITION OF PEGINTERFERON ALFA-2B DURING LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY INCREASES HBEAG SEROCONVERSION AND HBSAG DECLINE – WEEK 48 RESULTS FROM A MULTICENTER RANDOMIZED CONTROLLED TRIAL (PEGON STUDY) FIXED-DOSE ORAL COMBINATION THERAPY WITH DACLATASVIR/ASUNAPREVIR/BECLABUVIR, ± RIBAVIRIN, FOR PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION AND COMPENSATED CIRRHOSIS: UNITY-2 PHASE 3 RESULTS ALL-ORAL, FIXED-DOSE COMBINATION THERAPY WITH DACLATASVIR/ASUNAPREVIR/BECLABUVIR FOR PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION WITHOUT CIRRHOSIS: UNITY-1 PHASE 3 RESULTS SOFOSBUVIR IN COMBINATION WITH RIBAVIRIN FOR 12 WEEKS ACHIEVES 97% SVR12 IN JAPANESE PATIENTS WITH CHRONIC GENOTYPE 2 HEPATITIS C INFECTION THE CHARACTERISTIC CHANGES IN HEPATITIS B VIRUS X REGION FOR HEPATOCELLULAR CARCINOMA: A COMPREHENSIVE ANALYSIS BASED ON GLOBAL DATA STRATEGY OF SURGICAL TREATMENT USING MICROWAVE COAGULO-NECROTIC THERAPY FOR UNRESECTABLE MULTIPLE COLORECTAL LIVER METASTASES EFFICACY AND SAFETY OF PEGINTERFERON LAMBDA-1A WITH OR WITHOUT DACLATASVIR COMPARED WITH PEGINTERFERON ALFA-2A, EACH IN COMBINATION WITH RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 2 OR 3 INFECTION EXPRESSION OF ABC TRANSPORTER, BILE SALT EXPORT PUMP, IS INVERSELY CORRELATED WITH NAFLD ACTIVITY SCORE IN THE LIVER OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE THE ROLE OF GENETIC VARIABILITY OF PNPLA3 (RS738409) ON HISTOLOGICAL PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE